Free Trial

Kymera Therapeutics (KYMR) Insider Trading & Ownership

Kymera Therapeutics logo
$44.05 +1.21 (+2.82%)
(As of 11/20/2024 ET)

Kymera Therapeutics (NASDAQ:KYMR) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
15.82%
Number Of
Insiders Buying
(Last 12 Months)
0
Number Of
Insiders Selling
(Last 12 Months)
8
Amount Of
Insider Selling
(Last 12 Months)
$40.18 M
Get KYMR Insider Trade Alerts

Want to know when executives and insiders are buying or selling Kymera Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

KYMR Insider Buying and Selling by Quarter

Kymera Therapeutics Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/17/2024Pamela EspositoDirectorSell13,500$48.28$651,780.00  
8/26/2024Jeffrey W. AlbersDirectorSell5,000$49.10$245,500.00  
7/16/2024Jared GollobInsiderSell23,145$45.81$1,060,272.45  
7/9/2024Bruce BoothDirectorSell453,960$38.21$17,345,811.60  
6/12/2024Bruce BoothDirectorSell16,740$35.45$593,433.00  
6/7/2024Joanna HorobinDirectorSell8,500$32.99$280,415.00  
[625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Register for the FREE Workshop Now & get $10 in Bitcoin
3/15/2024Bruce BoothDirectorSell71,764$40.46$2,903,571.44  
3/13/2024Bruce BoothDirectorSell139,255$42.23$5,880,738.65  
3/13/2024Venture Fund X L.P. AtlasMajor ShareholderSell115,090$42.23$4,860,250.70  
3/11/2024Bruce BoothDirectorSell51,184$42.85$2,193,234.40  
3/11/2024Venture Fund X L.P. AtlasMajor ShareholderSell42,302$42.85$1,812,640.70  
3/4/2024Bruce N JacobsCFOSell3,934$41.86$164,677.24  
2/21/2024Jeffrey W. AlbersDirectorSell4,385$39.05$171,234.25  
2/9/2024Jared GollobInsiderSell46,137$35.50$1,637,863.50  
1/23/2024Jeffrey W. AlbersDirectorSell10,000$30.05$300,500.00  
1/4/2024Ellen ChiniaraInsiderSell3,295$22.58$74,401.10  
(Data available from 1/1/2013 forward)

KYMR Insider Trading Activity - Frequently Asked Questions

The list of insiders at Kymera Therapeutics includes Bruce Booth, Bruce N Jacobs, Bvf Partners L P/Il, Ellen Chiniara, Jared Gollob, Jeffrey W. Albers, Joanna Horobin, Nello Mainolfi, Pamela Esposito, and Venture Fund X L.P. Atlas. Learn more on insiders at KYMR.

15.82% of Kymera Therapeutics stock is owned by insiders. Learn more on KYMR's insider holdings.

The following insider purchased KYMR shares in the last 24 months: Bvf Partners L P/Il ($3,179,833.74).

Insiders have purchased a total of 238,516 KYMR shares in the last 24 months for a total of $3,179,833.74 bought.

The following insiders have sold KYMR shares in the last 24 months: Bruce Booth ($40,804,952.51), Bruce N Jacobs ($207,147.24), Ellen Chiniara ($74,401.10), Jared Gollob ($2,698,135.95), Jeffrey W. Albers ($717,234.25), Joanna Horobin ($280,415.00), Pamela Esposito ($651,780.00), and Venture Fund X L.P. Atlas ($16,610,449.57).

Insiders have sold a total of 1,706,287 Kymera Therapeutics shares in the last 24 months for a total of $62,044,515.62 sold.

Kymera Therapeutics Key Executives

  • Dr. Bruce L. Booth DPHIL (Age 50)
    Ph.D., Co-Founder & Independent Chairman
    Compensation: $75k
  • Dr. Nello Mainolfi M.D. (Age 45)
    Ph.D., Co-Founder, President, CEO & Director
    Compensation: $1.08M
  • Mr. Bruce N. Jacobs CFAMr. Bruce N. Jacobs CFA
    Chief Financial Officer
  • Dr. Jeremy G. Chadwick Ph.D. (Age 61)
    Chief Operating Officer
    Compensation: $883k
  • Ms. Ellen V. Chiniara Esq. (Age 65)
    J.D., Chief Legal Officer & Corporate Secretary
    Compensation: $640.35k
  • Dr. Jared A. Gollob M.D. (Age 59)
    Chief Medical Officer
    Compensation: $723.6k
  • Ms. Karen Weisbach
    Head of People & Culture
  • Dr. Juliet Williams B.A Ph.D.
    Head of Research


This page (NASDAQ:KYMR) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners